Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and PK of [14C]SJP-0008 in healthy male subjects
NCT05320861Phase 1Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SJP-0008 in central retinal artery occlusion (CRAO), sponsored by Senju Pharmaceutical Co., Ltd. Primary endpoint: Mass balance recovery of total radioactivity in all excreta at Day 10. Started Sep 2021; status: completed.
02
Drugs
SJP-0008
03
Conditions
central retinal artery occlusion (CRAO)
Beyond the preview
Go deeper on NCT05320861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320861.